Serotonin 6 Receptor Antagonists Market: Competitive Landscape, Pipeline, and Market Analysis 2024

The 5HT6 receptor is a subtype of the 5HT receptor that binds the endogenous neurotransmitter serotonin (5-hydroxytryptamine, 5HT). It is a G protein-coupled receptor (GPCR) that is coupled to Gs and mediates excitatory neurotransmission. The 5HT6 receptor is expressed almost exclusively in the brain. It is distributed in various areas including, but not limited to, the olfactory tubercle, cerebral cortex (frontal and entorhinal regions), nucleus accumbens, striatum, caudate nucleus, hippocampus, and the molecular layer of the cerebellum. Based on its abundance in extrapyramidal, limbic, and cortical regions it can be suggested that the 5HT6 receptor plays a role in functions like motor control, emotionality, cognition, and memory. The mechanism of action of Serotonin 5-HT6 receptor antagonists involves blocking or inhibiting the activity of the 5-HT6 receptors. By doing so, these drugs can modulate serotonin signaling in the brain, leading to various effects such as Enhancing cognition and modulating neurotransmitter release, serotonin system plays a crucial role in regulating mood, emotions, and behavior. Modulating serotonin signaling through 5-HT6 receptor antagonists may affect mood disorders, anxiety, and depression. Serotonin 6 Receptor Antagonists have been identified as an effective therapeutic strategy for CNS disorders, psychotic disorders, delirium, neurodegenerative diseases, movement disorders, and reperfusion injury to name a few. The increased prevalence of neurological diseases is the key driver for the Serotonin 6 Receptor Antagonists market. For instance, according to the World Health Organization, an estimated 8.2 million people lived with neurological disability in 2019. Moreover, to overcome difficulties in therapy, various market players are developing innovative compounds. For instance, Lundbeck’s Lu AF35700 for the indication of Schizophrenia is under the various stages of clinical studies.

Key Market Developments:

• In October 2022, Lundbeck completed phase 3, an interventional, randomized, double-blind, active-controlled, fixed-dose study of Lu AF35700 in patients with treatment-resistant schizophrenia.

Drugs under the Pipeline for Serotonin 6 Receptor Antagonists:

Idalopirdine (Lu AE58054)

Lu AF35700

Cerlapirdine (PF-5212365)

Intepirdine (SB-742457)

PF-05212377

Masupirdine (SUVN-502)

ABT 354

AVN-101

Brilaroxazine (RP5063)

Landipirdine (SYN120)

Clinical Activity and Developments of Serotonin 6 Receptor Antagonists:

Till July 2023, more than 10 companies have approximately 10 molecules targetting a number of CNS diseases. For these molecules, more than 2 clinical trials are being conducted; most are in phase-2 and phase-3 clinical trials by players across the globe. For instance,

• In May 2019, Lundbeck completed phase 3, a randomized, double-blind, parallel-group, placebo-controlled study of Idalopirdine in patients with mild-moderate Alzheimer's Disease treated with an acetylcholinesterase inhibitor.
• In June 2019, GSK completed phase 2, a double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of SB-742457, Donepezil, and placebo on cognition in subjects with mild to moderate Alzheimer's Disease.